3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro

Molecular Pharmacology

Volumn 63, Issue 6, 2003, Pages 1223-1229

  Setola, Vincent ^a   Hufeisen, Sandra J ^a   Grande Allen, K Jane ^b   Vesely, Ivan ^b   Glennon, Richard A ^c   Blough, Bruce ^d   Rothman, Richard B ^e   Roth, Bryan L ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d RTI INTERNATIONAL   (United States)

^e NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; DEXFENFLURAMINE; DIHYDROERGOTAMINE; FENFLURAMINE; NORFENFLURAMINE; PERGOLIDE; RECOMBINANT RECEPTOR; SEROTONIN 2B RECEPTOR;

ARTICLE; CELL PROLIFERATION; DRUG ABUSE; DRUG EFFECT; DRUG POTENCY; HEART VALVE; HUMAN; HUMAN CELL; MITOGENICITY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RECEPTOR BINDING; RECEPTOR UPREGULATION; VALVULAR HEART DISEASE;

3,4-METHYLENEDIOXYAMPHETAMINE; ANIMALS; CELL DIVISION; CELLS, CULTURED; COS CELLS; FENFLURAMINE; HEART VALVE DISEASES; HUMANS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NORFENFLURAMINE; RECEPTOR, SEROTONIN, 5-HT2B; RECEPTORS, SEROTONIN; SEROTONIN AGENTS;

EID: 0038779278     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.63.6.1223     Document Type: Article

References (22)

1. Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, Higenbottam T, Oakley C, Wouters E, Aubier M, et al. (1996) Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 335:609-616.
2. Baumann MH, Ayestas MA, Dersch CM, Partilla JS, and Rothman RB (2000) Serotonin transporters, serotonin release and the mechanism of fenfluramine neurotoxicity. Ann NY Acad Sci 914:172-186.
3. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, and Schaff HV (1997) Valvular heart disease associated with fenfluraminephentermine. N Engl J Med 337:581-588.
4. Creutzig A (1992) Ergotamine-induced heart valve fibrosis and coronary microangiopathy? Dtsch Med Wochenschr 117:1736.
5. de la Torre R, Farre M, Ortuno J, Mas M, Brenneisen R, Roset PN, Segura J and Cami J (2000) Non-linear pharmacokinetics of MDMA ('ecstasy') in humans. Br J Clin Pharmacol 49:104-109.
6. 2B receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol 57:75-81.
7. Jick H, Vasilakis C, Weinrauch LA, Meier CR, Jick SS, and Derby LE (1998) A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. N Engl J Med 339:719-724.
8. Launay JM, Herve P, Peoc'h K, Tournois C, Callebert J, Nebigil CG, Etienne N, Drouet L, Humbert M, Simonneau G, et al. (2002) Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med 8:1129-1135.
9. Nash JF, Roth BL, Brodkin JD, Nichols DE, and Gudelsky GA (1994) Effect of the R(-) and S(+) isomers of MDA and MDMA on phosphatidyl inositol turnover in cultured cells expressing 5-HT2A or 5-HT2C receptors. Neurosci Lett 177:111-115.
10. Nebigil CG, Choi DS, Dierich A, Hickel P, Le Meur M, Messaddeq N, Launay JM, and Maroteaux L (2000a) Serotonin 2B receptor is required for heart development. Proc Natl Acad Sci USA 97:9508-9513.
11. Nebigil CG, Launay JM, Hickel P, Tournois C, and Maroteaux L (2000b) 5-Hydroxytryptamine 2B receptor regulates cell-cycle progression: cross-talk with tyrosine kinase pathways. Proc Natl Acad Sci USA 97:2591-2596.
12. Pritchett AM, Morrison JF, Edwards WD, Schaff HV, Connolly HM, and Espinosa RE (2002) Valvular heart disease in patients taking pergolide. Mayo Clin Proc 77:1280-1286.
13. Roth BL, Baner K, Westkaemper R, Siebert D, Rice KC, Steinberg S, Ernsberger P, and Rothman RB (2002) Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proc Natl Acad Sci USA 99:11934-11939.
14. Rothman RB and Baumann MH (2002) Therapeutic and adverse actions of serotonin transporter substrates. Pharmacol Ther 95:73-88.
15. Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, and Partilla JS (2001) Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39:32-41.
16. 2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 102:2836-2841.
17. Roy A, Brand NJ, and Yacoub MH (2000) Expression of 5-hydroxytryptamine receptor subtype messenger RNA in interstitial cells from human heart valves. J Heart Valve Dis 9:256-261.
18. Sheffler DJ and Roth BL (2003) Salvinorin A: the 'magic mint' hallucinogen finds a molecular target in the kappa opioid receptor. Trends Pharmacol Sci 24:107-109.
19. Steffee CH, Singh HK, and Chitwood WR (1999) Histologic changes in three explanted native cardiac valves following use of fenfluramines. Cardiovasc Pathol 8:245-253.
20. Weissman NJ (2001) Appetite suppressants and valvular heart disease. Am J Med Sci 321:285-291.
21. Weissman NJ, Tighe JF Jr, Gottdiener JS, and Gwynne JT (1998) An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group. N Engl J Med 339:725-732.
22. 2 receptor and its signaling pathway in aortic valve interstitial cells. Am J Pathol 161:2209-2218.